AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Declaration of Voting Results & Voting Rights Announcements Feb 3, 2020

7612_rns_2020-02-03_695e9769-5c2e-4aab-8fa8-56ca0c725793.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3173B

Eco Animal Health Group PLC

03 February 2020

3 February 2020

ECO Animal Health Group PLC

Total Voting Rights and Share Capital

ECO Animal Health Group PLC (the "Company") announces that the total number of ordinary shares of 5 pence each in the Company as at the date of this notice is 67,547,626. There are currently nil shares held in treasury. 

The total number of voting rights in the Company is therefore 67,547,626. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

For further information, please contact:

ECO Animal Health Group plc

Marc Loomes (CEO)

Christopher Wilks (CFO)
020 8447 6906
N+1 Singer (Nominated Adviser & Joint Broker)

Mark Taylor

Peter Steel

Alex Bond
020 7496 3000
Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden
020 7418 8900
IFC Advisory

Graham Herring

Zach Cohen
020 3934 6630

About ECO Animal Health Ltd

ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVREAFFNALSEEFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.